Recently available cancer sequencing data have revealed a complex view of the cancer genome containing a multitude of mutations, including drivers responsible for cancer progression and neutral passengers. Measuring selection in cancer and distinguishing drivers from passengers have important implications for development of novel treatment strategies. It has recently been argued that a third of cancers are evolving neutrally, as their mutational frequency spectrum follows a 1/f power law expected from neutral evolution in a particular intermediate frequency range. We study a stochastic model of cancer evolution and derive a formula for the probability distribution of the cancer cell frequency of a subclonal driver, demonstrating that driver...
International audienceRecent evidence arising from DNA sequencing of healthy human tissues has clear...
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and...
Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation i...
Next-generation sequencing data from human cancers are often difficult to interpret within the conte...
The vast majority of mutations in the exome of cancer cells are passengers, which do not affect the ...
Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic dat...
We develop a branching process with accumulating mutations to model neutral tumor evolution. Further...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
In order to analyze data from cancer genome sequencing projects, we need to be able to distinguish c...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
Now published in Nature Genetics doi: 10.1038/s41588-018-0128-6Recent studies have identified preval...
Increasing evidence shows that tumor clonal architectures are often the consequence of a complex bra...
Cancer progression is determined by the accumulation of a number of key mutations. These can be coar...
Abstract Background Detailed modelling of the neutral mutational process in cancer cells is crucial ...
International audienceRecent evidence arising from DNA sequencing of healthy human tissues has clear...
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and...
Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation i...
Next-generation sequencing data from human cancers are often difficult to interpret within the conte...
The vast majority of mutations in the exome of cancer cells are passengers, which do not affect the ...
Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic dat...
We develop a branching process with accumulating mutations to model neutral tumor evolution. Further...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
In order to analyze data from cancer genome sequencing projects, we need to be able to distinguish c...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recen...
Now published in Nature Genetics doi: 10.1038/s41588-018-0128-6Recent studies have identified preval...
Increasing evidence shows that tumor clonal architectures are often the consequence of a complex bra...
Cancer progression is determined by the accumulation of a number of key mutations. These can be coar...
Abstract Background Detailed modelling of the neutral mutational process in cancer cells is crucial ...
International audienceRecent evidence arising from DNA sequencing of healthy human tissues has clear...
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and...
Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation i...